Email this article 
The prognostic value of repeated prostate fusion biopsy
- Authors: Zyryanov AV1, Keln Aa1, Surikov A.S.2, Ponomarev A.V.2, Kupchin A.V.2, Lebedev A.V.2, Popov I.B.2
-
Affiliations:
- Regional Urological center, МSP "Neftyanik", Department of Oncourological
- Regional Urological Center “Neftyanik”
- Issue: Vol 13, No 3 (2017)
- Pages: 71-75
- Section: PROSTATE CANCER
- Published: 30.09.2017
- URL: https://oncourology.abvpress.ru/oncur/article/view/674
- DOI: https://doi.org/10.17650/1726-9776-2017-13-3-71-75
- ID: 674
Cite item
Full Text
Abstract
Objective – disclosure of the main advantages of prostate biopsy under the magnetic resonance imaging (MRI) control, consideration of technical aspects of its implementation.
Materials and methods. Advances in multiparametric MRI have lead to improved detection of prostate tumors. The fusion of MRI data with transrectal ultrasound enables the targeted biopsy of suspicious areas. The results of fusion-biopsy were analyzed in 38 patients. The mean age of patients was 61.3 (44–70) years. All the patients underwent at least 1 transrectal prostate biopsies. The average number of biopsy cores was 24.3 (17–30), the average value of total prostate-specific antigen before saturation biopsy was 10,4 (0.20 to 34.16) ng/ml.
Results. Prostate cancer was diagnosed in 52.7 % of cases (20/38). Better prostate cancer detectability during repeated saturation biopsy generally occurred due to the localized forms of the disease (93.3 %).
Conclusion. Fusion biopsy allows prediction of a pathological stage of prostate cancer, Gleason grade of a tumor and its site localization with a greaterprobability. Most tumors detectable by saturation biopsy were clinically significant, which makes it possible to recommend fusion biopsy to some cohort of high prostate cancer risk patients.
About the authors
A V Zyryanov
Regional Urological center, МSP "Neftyanik", Department of Oncourological
Email: zav1965@mail.ru
Head of Department Oncourology at Regional Urological center, МSP "Neftyanik", Tyumen
Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
Russian FederationA a Keln
Regional Urological center, МSP "Neftyanik", Department of Oncourological
Author for correspondence.
Email: artyom-keln@yandex.ru
Surgeon at Regional Urological center, МSP "Neftyanik", Department of Oncourological, Tyumen
Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
Russian FederationA. S. Surikov
Regional Urological Center “Neftyanik”Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
A. V. Ponomarev
Regional Urological Center “Neftyanik”Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
A. V. Kupchin
Regional Urological Center “Neftyanik”Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
A. V. Lebedev
Regional Urological Center “Neftyanik”Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
I. B. Popov
Regional Urological Center “Neftyanik”Build 1, 8 Yuriya Semovskikh St., Tyumen’ 625000, Russia
References
Supplementary files
